Category Archives: Cell Biology

Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ – NeighborWebSJ

Regenerative Medicine Market Major Players:

Players active in the global regenerative medicine market include Osiris Therapeutics, Cook Biotech, Organogenesis, Baxter International, Inc., Stryker and RTI surgical, LifeSciences, CryoLife, Advanced Cell Technology, Sanofi, BioMimetic Therapeutics, Medtronic, StemCellsInc, and LifeCell Kinetic Concepts, among others.

ALSO READ :https://sapanas.tumblr.com/post/631130245458739200/regenerative-medicine-market-competitive-analysis

Regenerative Medicine Market Outlook

Global regenerative medicine market is growing continually, witnessing a massive uptake. Market growth primarily attributes to the increasing advancement in healthcare technology and the growing prevalence of chronic diseases. Besides, improvements in the field of regenerative medicine and stem cell technology drive the growth of the market excellently.

Moreover, the rising uptake of therapeutics such as stem cell biology, cellular therapy, tissue engineering in applications, including cord blood, oncology, urology, orthopedics, neurology, dermatology, and others accelerate the market growth. According to Market Research Future (MRFR), the global regenerative medicine market is poised to grow at 25.4% CAGR throughout the forecast period (2016 2022).

ALSO READ :https://yarabook.com/read-blog/138540

Additionally, the rising uptake of stem cell & tissue engineering processes in the treatment of health issues ranging from orthopedics, musculoskeletal & spine, dental, and skin/integumentary to cancer, neurology, and cardiology substantiate the market growth. Furthermore, the increasing rate of road accidents, injuries, and trauma cases drive the market exponentially, driving the demand for transplants & surgical reconstruction procedures.

On the other hand, factors such as the lack of awareness, skilled professionals, and stringent regulatory policies are projected to act as significant impeders for market growth. Nevertheless, funding support for the development of regenerative medicines would support the growth of the market throughout the predicted period. Also, widening application areas of regenerative medicines in the field of stem cell reconstructive and skin grafting would increase the market growth.

Global Regenerative Medicine Market Segments

The analysis is segmented into four dynamics;

By Material: Synthetic Materials, Genetically Engineered Materials, Pharmaceuticals, and others.

By Therapy: Stem Cell Biology, Cellular Therapy, Tissue Engineering, and others.

By Application: Cord Blood, Oncology, Urology, Orthopedics, Neurology, Dermatology, and others.

ALSO READ :http://www.marketwatch.com/press-release/fram-market-2021-industrytrends-opportunities-market-volume-competitive-landscape-possible-challenges-and-forecast-to-2025-2021-01-06

By Regions: Americas, Europe, Asia Pacific, Middle East & Africa, and Rest-of-the-World.

Regenerative Medicine Market Regional Analysis

North America is projected to continue dominating the globalregenerative medicine marketthroughout the forecast period. In 2015, North America accounted for more than 44% of the overall market share. This huge market growth attributes to the presence of a large number of major players and pharma & biotechnology companies. Moreover, huge investments made by public & private organizations drive the regenerative medicine industry in the region.

Besides, the rising prevalence of chronic diseases and orthopedic issues and increasing clinical trials to evaluate the therapeutic potential of products foster regional market growth. Also, the well-spread awareness towards the therapeutic potency of regenerative medicines impacts the market growth positively. The North American regenerative medicine market is expected to grow at a robust CAGR of 22.3% over the review period.

Europe stands second in the global regenerative medicine market. Factors such as the increasing per capita healthcare expenses and penetration of healthcare sectors in the region boost the market growth. Additionally, the rising government support and R&D funding in the life science developments substantiate the regional market growth. Markets in the UK, Germany, and France, contribute to the regional market majorly. The European regenerative medicine market is estimated to grow at 22.5% CAGR during the assessment period.

ALSO READ :http://www.marketwatch.com/press-release/m2m-communication-market-demand-to-rise-amid-industrial-automation-industry-analysis-with-business-trends-covid19-outbreak-competitor-strategyforecast-to-2023-2021-01-05

The Asia Pacific regenerative medicine market has emerged as a rapidly growing market. Factors such as the large advances in biotechnology and increasing government support for R&D are fostering the growth of the regional market. Regenerative medicine markets in highly populated countries such as China, India, and Japan support the regional market growth excellently, heading with huge technological advances. The APAC Regenerative Medicine market is predicted to demonstrate huge growth potential.

Global Regenerative Medicine Market Competitive Analysis

The well-established regenerative medicine market appears to be highly competitive with the presence of several notable players. To gain a larger competitive advantage, market players incorporate strategic initiatives such as mergers & acquisitions, expansions, and product/technology launch. Also, they make substantial investments to drive R&D to develop their capabilities and to expand their global footprints. Simultaneously, R&D funding programs initiated by the governments to enhance regenerative medicine capabilities are offering high growth potential. This is further going to attract several new entrants to the market and intensify the market competition further.

Regenerative Medicine Industry/Innovations/Related News:

March 15, 2020 - Research team at the University of Sheffield published their study on stem cell mutations that could improve regenerative medicine in the magazine Stem Cell Reports. Their study gives new insights into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring. It also suggests ways to reduce the likelihood of variations occurring in these cells when cultured. There is considerable interest in using Pluripotent stem cells to produce cells that can replace diseased or damaged tissues in applications referred to as regenerative medicine.

ALSO READ :http://www.marketwatch.com/press-release/waste-to-energy-market-share-size-key-players-regional-study-and-forecast-2024-2020-12-30

https://neighborwebsj.com/

See the original post:
Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ - NeighborWebSJ

Global Live Cell Imaging Market Size is Expected to reach USD 3529.26 Million by 2025 and Registeri – PharmiWeb.com

GlobalLive Cell ImagingMarket Research Report and Forecast 2020-2025is the latest report byFior Marketswhich is the fastest growing market research company. The report provides a comprehensive scope of the market which includes future supply and demand scenarios, changing market trends, high growth opportunities, and in-depth analysis of the future market prospects. The report features real-time developments in the globalLive Cell Imagingmarket encompasses a highly structured and comprehensive outlook of the market. It shows market types and applications that are categorized as ideal market segments. The report covers the competitive data analysis of the emerging and prominent players of the market. Along with this, it provides comprehensive data analysis on the risk factors, challenges, and possible new market avenues.

The report has viewed the current top players and the forthcoming contenders. Business procedures of the vital participants and the new entering market ventures are concentrated in detail in this report. The report also encompasses SWOT investigation, income offer, and contact data. The report throws light on specific drivers, restraints, opportunities, challenges, and other determinants that tremendously favor and oppose normal growth in the globalLive Cell Imagingmarket. It also covers the product pricing factors, growth, emerging and dominant trends, overall market dynamics, and market size. The report includes a wide spectrum of the market to provide insightful data for the forecast period 2020-2025.

Global live cell imaging market is expected to reach USD 3,529.26 Million by 2025, at a CAGR of 8.97% from 2018 to 2025

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post the COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/386014/request-sample

The report gives the market segments that have been fragmented into sub-segments. The study gives a transparent view of the global market and includes a thorough competitive scenario and portfolio of the key players functioning in it. The report offers fundamental opinions regarding the market landscape, emerging and high-growth sections of the globalLive Cell Imagingmarket, high-growth regions, and market drivers, restraints, and also market chances. It targets estimating the current market size and growth potential of the global market across sections such as also applications and representatives.

Competitive Analysis:

Te report accurately profiles key vendors and players functioning in the globalLive Cell Imagingmarket, in terms of their ranking and core competencies, together with determining the competitive landscape. It also studies competitive developments such as partnerships and collaborations, mergers, and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the global market.

The top key players profiled in this report are:Danaher Corporation, Carl Zeiss AG, Nikon Corporation, Olympus Corporation, PerkinElmer, Inc., GE Healthcare, Bruker Corporation, Thermo Fisher Scientific Inc., Sartorius AG, BioTek Instruments, Etaluma, Inc., CytoSMART Technologies, NanoEnTek Inc., Leica Microsystems, Dickinson and Company, Becton, Sigma-Aldrich Corporation, Molecular Devices, LLC

Other Segment Analysis:

Segment classification of the market structure has been encouraged by our research experts to allow readers to comprehend the versatility of the market in terms of product and service variation. The market has been examined with vital market-specific developments across segment categories. Market segments such as type and application are also determined by quantitative and qualitative review. Type market size bifurcated into its product typeInstruments, Consumables, Software, Servicesin terms of Volume (K Units) and Value (USD Million). Market segment by application, split into:Cell Biology, Stem Cells, Developmental Biology, Drug Discovery

Request forCustomization:https://www.fiormarkets.com/enquiry/request-customization/386014

Country-Wise Assessment:

The report presents an understanding of the regional, country, and even local developments. Overview of globalLive Cell Imaging market dynamics such as industry outlook, value chain developments, SWOT and PESTEL assessment as well as Porters Five Point analysis. The report also encompasses crucial analytical reviews on key elements, trends, current, and future perspectives. By regional analysis, the report covers:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/live-cell-imaging-market-by-product-instruments-consumables-386014.html

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Contact UsMark StonePhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Originally posted here:
Global Live Cell Imaging Market Size is Expected to reach USD 3529.26 Million by 2025 and Registeri - PharmiWeb.com

Trabecular bone organoid model for studying the regulation of localized bone remodeling – Science Advances

Trabecular bone maintains physiological homeostasis and consistent structure and mass through repeated cycles of bone remodeling by means of tightly localized regulation. The molecular and cellular processes that regulate localized bone remodeling are poorly understood because of a lack of relevant experimental models. A tissue-engineered model is described here that reproduces bone tissue complexity and bone remodeling processes with high fidelity and control. An osteoid-inspired biomaterialdemineralized bone paperdirects osteoblasts to deposit structural mineralized bone tissue and subsequently acquire the resting-state bone lining cell phenotype. These cells activate and shift their secretory profile to induce osteoclastogenesis in response to chemical stimulation. Quantitative spatial mapping of cellular activities in resting and activated bone surface coculture showed that the resting-state bone lining cell network actively directs localized bone remodeling by means of paracrine signaling and cell-to-cell contact. This model may facilitate further investigation of trabecular bone niche biology.

Read the original:
Trabecular bone organoid model for studying the regulation of localized bone remodeling - Science Advances

Aging Starts at 30 In Your Body. Here’s What to Do About it – The Beet

You know how every decade your body loses muscle mass, and adds more fat, in what is considered an inevitable downward spiral into aging? This process is called sarcopenia and "sad to say, it starts inyour 30s," according to Susan Vannucci, RD, Ph.D. Asyour body's lean muscle mass decreases, "we not only lose strength but our basal metabolic rate or the amount of energy or calories your body needs every day becomes reduced." And that means weight gain! This process accelerates with age, making it more and more difficult to even maintain, much less lose, weight.

Well, there is a way you can fight it. But first, you have to acknowledge that the changes that happen over time don't just pop up one day, but rather are insipient and gradual, and they have everything to do with the choices you make at the table and in your workout routine.Here's the good news: You can control all that.

Just as the beauty industry has taught young people to wear sunscreen at the beach when they don't have a wrinkle in sight, so does the nutritionist savvy authorities (not the food industry, but theprofessionals who you pay to give you smart nutrition advice), want you to think about eating the healthiest foods and doing resistance traininglike burpees, kettlebells, weights, and HIIT workouts) that put your muscles under stresson a regular basis.

The only debate is: What are the right foods to eat? And how can you harness the powers of antioxidants to spring your cells into action, to fight off inflammation, repair their own cellular infrastructure, andfunction optimally, as they do in a young person, for decades to come?

"Aging is not a disease. There are diseases of aging, but it doesn't mean they are inevitable," says Vannucci, RD, Ph.D. a wellness expert in New YorkCity who provides individual wellness counseling in-person and online for individuals age 45 and up nationwide. Su, as her patients call her, has a strong academic and medical background, having gotten her degree in cellular biology, as well as training in nutrition. She is currently working on a book, Age Strong, Live Long with her kick-ass trainer, Antoinette Vo, who has her doing 60-pound deadlifts at the age of 71.

"I ran my last marathon for my sixtieth birthday, and it was my fastest," Vannucci explains. She retired her running shoes to save her back, after a few issues, but her current workouts of strength training, Pilates and power walking, and what she calls "heavy lifting" have made her stronger than she was decades ago. "My attitude is that you can forestall aging, and by and large, unless you have a genetic condition, all of the diseases related to aging are not inevitable. Loss of muscle mass and body fat are not inevitable. You just have to work at it."

Because she started her career asa scientist her patients are likelier to listen to her. So when her patients askher the mechanisms of how something works and why, if she doesn't know the answer she will find it out.The questions we asked her today are simple: How can you eat and workout to reverse the clock, or at least slow the hands of time, to make sure when you hit your 60th or 70th birthday your body is as fit or fitter than it was at half that age?

Susan Vannucci: The thing about food is it definitely impacts aging.If you want to forestall the process of aging, you need to reduce systemic inflammation. Because it's reallythe same thing. Inflammation causes aging, on a cellular level. So first you have to get everything out of your body that causes inflammation. That is red processed meat, chemicals, added sugar, and anything that is processed.

Years ago, Time magazine did a big cover story on inflammation, calling it the Silent Killer. Inside the writer calls it"Inflam-aging." It is such a great term! You think about inflammation, such as when you cut yourself or bruise yourself, but that is a momentary stream of helpful fluid to repair a site. The concept we are talking about is not that temporary state of cell repair. It's more like a flood-state that suppresses all cellular functions. When you have systemic inflammation in your bodythatis chronic, thatis one of the biggest contributors to aging.

Susan Vannucci: I tell clients: The biggest problem is junk food and added sugar in the diet.The fact that people don't even know how big the basket of junk food is. They might think they are eating healthy but even if it is vegetarian or vegan, just because it is lacking animal product does not mean it's healthy! it may be so processed that it's junk food. Read the label. Most packages foods are so full of chemicals.

In the effort to lower inflammation, eat more plant-based foods.But eat them in their whole form. potato chips and corn chips are still plant-based.

Susan Vannucci: When my daughter was a teenager, said she wanted to go vegetarian. I worried that to her, that meant a diet high in potato chips. I made a deal with her. She was a competitive athlete, a sprinter, and hurdler, a competitive horsewoman and I made a deal with her: You heed a healthy diet, and I will totally support you. You have to be able to eatall the beans and legumes and plant-based proteins that are whole foods and recognize what makes a complete protein.

She and I were always going to write this book together on what to do when your child announces they want to go vegetarian or vegan. She stuck with it until she married a guy who likes meat, then she got pregnant and so now the way she eats is thatany meat in her diet is more of a condiment than the main part of the meal.

Susan Vannucci: The first thing is we talk about what they are already doing to get a sense of where they arein this journeybecause I always say I don't put people in diets. We don't talk about being "good" or "bad," and I don't weigh anybody. I provide the information they need and assume we are all responsible adults and if you want to do this, you can.

Susan Vannucci: Get rid of all the white stuff. Things that are processed. Most things that come in bags, boxes, or containers of any kind can sit on a truck or a shelf for a long time ... the chemicals in it are the problem. Get rid of that stuff. Flip to whole grains, whole foods, lots of water, and move more! That should not be so hard to do.

When people start to read the labels of boxes that hold the food they are about to eat, thinking they are healthy foods, like whole wheat crackers, they can be horrified. How many names do we have for sugar? Not uncommonly if you look on a label there will be three to five kinds of sugar in there.

Susan Vannucci:If someone isreally hungry (not bored or in need of a diversion) cut-up vegetables. carrots, celery with a little bit of hummus, or some edamame is a really good snack. A lot people come to me with the same complaint. When they worked all day in an office and get to the end of the day, and leave to go home,by the time they get home, they are starving. They walk in the front door and eat everything in sight. While waiting for dinner. Usually, that sets their cravings up. Now when we work from home it's constant snacking.

If you know you're a snacker keep healthy ones on hand: Rice cakes, hummus, and make avocado slices. Rice cakes can be healthy but not the caramel corn ones loaded with sugar. Just basically talking about whole grain rice cakes. They keep! And also keep nuts around.

Susan Vannucci: As for eating plant-based, of course, most people should eat more vegetables, fruits, nuts, seeds, and whole grains. But that doesn't mean that just because you're vegan or avoiding animal products that you're eating healthy. You have to avoid all processed foods. I am an advocate for healthy foods and what works best for people is not all the same.

For the planet, and because I absolutely hate, loathe, and detest the food industry, I would saychoosing a diet of mostlyplant-based eating is smart. But I know people like my husband who especially don't do as well on a solely plant-based diet.

Susan Vannucci:Normally, people are worried about protein but unless you are over 80 a lack of protein is unlikely to be your biggest problem. People who are older can sometimes be deficient because they don't eat enough calories in general. But if you're not in that category it's not something to worry about.

Susan Vannucci:For keeping muscle mass and not gaining fat you need to put your muscles into a state of stress. I enjoy heavy lifting. As you get older and by that, I mean anyone over 30, with the awareness that this aging process of losing muscle mass starts in your 30s, you have to do resistance training, and it has to be heavy.

For the most part, women are not going to bulk up. The way I started this was when I stopped marathon running I just felt I was losing my strength, so I got a trainer who got me into kettlebells, and it's been fabulous. I am stronger than ever at 71, and I am pretty strong. I have my cadre of kettlebells and I can deadlift 100 pounds.

The idea is not to lose muscle mass, so you need to add in resistance training several days a week. and go heavy. I can swing a kettlebell that is 40 pounds, and lift 60, but not over my head (that's dangerous). I will lift 18 pounds over my head.This is how women, especially can maintain muscle mass. The reason we lose it is that the equilibrium in our body between muscle synthesis and muscle breakdown starts to shift as we get older. So you breakdown more than you build back up. And slowly over time, you lose your muscle mass. That's what causes aches, pains, falls, and lack of balance. The stronger the body, the less you age.

Susan Vannucci: Vitamin D3 is absolutely important.Almost no one gets enough D3 naturally. And Omega-3 is important, either from algae or fish oil. We have come to learn that vitamin D is essential in so many pathways. Way beyond just bone health. It's vital in fighting cancer, MS, and more. And because of sunscreen, and working indoors, staying out of the sun, people are vitamin D deficient. Yes, cases of COVID-19 have been worse for those who are D deficient, so taking D is a good idea to strengthen your ability to fight viruses.

Why Omega 3 because what's happened is we need all the omegas, the Omega-3s the Omega-6s, and the Omega-9s. But because of the food industry, ourdiets lack Omega-3. They have taken out the Omega-3 from foods, and increase the Omega-6 to increase things like shelf life. So for most people, the ratio is way out of balance. And what happens is our cell membranes are made of fat. They have a lipid bilayer and they are constantly turned over, like most things in the body, so if you have too much Omega-6 in your body, that gets overrepresented in your cell membranes, and then when anything happens, like internal stress and those Omega-6s get broken down, and they are pro-inflammatory. So you need to supplement with Omega-3 to keep your cell membranes healthy and intact.

Susan Vannucci: So that is why people are living with this internal fire.Inflammation is a precursor of a lot of diseases, and this is inflammation is something you can't see because it's going on inside of you on a cellular level. You can see the effects, like high blood pressure or you can take a blood test and test for what's called C-reactive protein.

That can be tested for, andthat's probably the easiest and most common marker for people. C-reactive protein is a marker that indicates there is inflammation in the body, and if yours is elevated it can be a signthat there's inflammation in the arteries of the heart, and that you are at risk for heart attack or stroke.High blood pressure is another sure sign of inflammation. If there should be an impetus to go to a plant-based diet it's hypertension. I tell people that the DASH. diet works which are mostly made up of plant foods.

To connect with Susan Vannucci, visit her website, Wellnesswith Susan Vannucci, Ph.D.

1. How old are you?20 or less = 0; 21-30 = 1; 31-40 = 2; 41-50 = 3; 51-60 = 4, >60 = 5

2. Have you had a heart attack or stroke? Yes = 5; No = 0

3. Do you have high blood pressure (>140/90), or high cholesterol ( >220; HDL<35)? Yes = 5; No = 0

4. Do you currently smoke?Yes = 5, go to question 5; No = 0, skip to 6

5. Do you smoke more than 10 cigarettes a day?Yes = 5, go to question 7; No = 0, go to question 7

6. Have you ever smoked regularly?No, never = 0; quit more than 10 years ago = 1; 5-10 years ago = 2; quit within the past 5 years = 3

7. Do you have diabetes- either type 1 or type 2? Yes = 5; No = 0

8. Do you have periodontitis (severe gum disease)? Yes = 3; No = 0

9. Do you have medical complaints but doctors cant find anything wrong? Yes = 3; No = 0

10. Are you often fatigued, even after a good night sleep? Yes = 5; No = 0

11. Do you have trouble falling asleep and/or wake up too early and cant go back to

sleep?Yes = 3; No = 0

12. What is your Body Mass Index (BMI)? Weight (lbs) x 704.5 / height (in)2 < 25 = 0; 25 29.9 = 3; >30 = 5

13. Do you feel depressed or sad most of the time? Yes = 3; No = 0

14. On an average day, how much pain do you have?No pain = 0; minor aches, nothing serious = 1; annoying pain = 2; sometimes a lot of pain, depends on the day = 3; usually in pain = 4

15. How often do you eat fish/ take omega-3 supplements/week? None = 3; 1 or 2 = 0; >3 = -3

16. How many servings of fruits and vegetables do you eat/day? None = 5; 1-3 = 3; 3-7 = 0; >7 = -5

17. What is the population size of where you live?> 1 million = 5; 500,000 1 million = 3; < 500,000 = 0

18. What fuel do you use for home heating?Kerosene burner/wood stove = 5; oil or gas furnace = 3; heat pump or electric = 0

19. How often do you use heavy-duty cleaning products (bleach, ammonia, bath, and shower cleaners, mildew removers, etc) in your home?

Never, only use natural cleaners = 0; rarely = 1; often = 2; daily = 4 20. Do you regularly use air fresheners, either spray or plug in? Yes = 2; No = 0

21. How often do you feel stressed?

Rarely = 0; About average = 1; Often = 2; Always = 5

22. How often do you exercise?

Never = 5; rarely (1x week or less) = 4; 1-2/week = 1; regularly,

3 or more/week = -523. Do you regularly take steroids either by prescription or performance- enhancing?

Yes = 5, No = 024. Do you take aspirin, ibuprofen, or other NSAIDs, or statin medication?

Yes = -5; No = 025. Are you exposed to pesticides?

Frequently = 5; Sometimes = 3; Never = 0 Total Inflammation Score =

Max = 98, Lowest = 18Your Score: 50- 98: High inflammation risk. Dont panic!! This only means you have a higher than average risk of developing the disease- but there are things you can do! Talk to your doctor ask about testing your C-reactive protein (CRP). And follow guidelines to reduce your risk score.Your Score: 20-49: Moderate inflammation risk. Look for areas where you scored the highest and plan ways to change those risk factors, especially with increased age.Your Score: < 20: Congratulations!! This is a great place to start towards a lifetime of wellness and disease prevention. Pay attention to areas that will increase risk in the future!

See the rest here:
Aging Starts at 30 In Your Body. Here's What to Do About it - The Beet

IsoPlexis secures $135M to boost its single-cell protein analysis tech – FierceBiotech

As single-cell analysis technologies continue their rapid developmentpromising a cells-eye view of protein interactions and signalingIsoPlexis hopes to establish itself as a provider of next-generation biology tools with $135 million in new financing.

Backed by Perceptive Advisors, the companys series D round includes $85 million in equity securities plus a $50 million credit facility, alongside support from Ally Bridge Group, funds managed by BlackRock and other investors.

IsoPlexis immediate plans are to expand its global sales and customer support teams, increase its commercial capacity and grow its R&D staff as it builds out its product development strategy, according to co-founder and CEO Sean Mackay.

Last November, the company debuted its IsoSpark instrument, with a tabletop footprint that aims to provide single-cell proteomics capabilities to large and small laboratories alike. IsoPlexis said it plans to begin shipments this month.

The major use of proceeds is to be able to meet the demand in the right places, for cancer immunology, cell and gene therapy and COVID, Mackay said in an interview with Fierce Medtech.

The second use of proceeds is really around the product road map, where we have in-licensed things to interrogate more aspects of single-cell biology, which includes the phospho-proteome, he added, referring to the bodys wide range of secreted proteins used to transmit messages to other cells and coordinate immune responses.

RELATED: Mission Bio raises $70M to scale single-cell cancer R&D platform

Using antibody-based proteomic barcodes, IsoPlexis hardware can tag and analyze hundreds of individual cells at once and classify each by the range of functional proteins they release.

This can help predict how certain patients may respond to checkpoint inhibitor-based cancer therapies or develop drug resistanceor give a better understanding of how the immune system may react or overreact to the coronavirus that causes COVID-19, including through a partnership with researchers at Yale University.

RELATED: Merck joins Seattle consortium to uncover COVID-19's molecular workings

Weve come out with papers showing that if you can measure more of these proteins concurrently with each single cell, you can start to resolve and treat the aberrant signaling pathways that were engaged, Mackay said.

What we hope to do is continue to popularize the need to look at the phospho-proteome, because the early data is so promising, he added. I think our platform opens up some new modalities to be able to answer critical questions about truly networked intracellular biology and how to interact with targeted inhibitors.

View post:
IsoPlexis secures $135M to boost its single-cell protein analysis tech - FierceBiotech

IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors – PRNewswire

BRANFORD, Conn., Jan. 7, 2021 /PRNewswire/--IsoPlexis, the leader in single-cell functional proteomics, today announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility. The round was led by Perceptive Advisors with participation from other new investors, Ally Bridge Group and funds and accounts managed by BlackRock, as well as other existing investors. IsoPlexis will use the proceeds from this financing to expand its global commercial and R&D teams, increase operational capacity to satisfy growing demand, and accelerate its next generation single-cell biology product development roadmap.

"We believe the future of advanced medicines will rely upon deeper access toin vivobiology for the development of new therapies and are excited to back the team at IsoPlexis," said Sam Chawla of Perceptive Advisors.

Michael Altman, of Perceptive Advisors continued, "IsoPlexis' unique technology is giving researchers this access through the convergence of dynamic proteomics and single cell biology. We are delighted to support IsoPlexis and their vision to accelerate the development of personalized therapeutics to significantly impact human health."

IsoPlexis' complete end-to-end solutions are empowered by breakthrough and proprietarysingle-cell functional proteomic technology, proteomic barcode chips, that allow researchers to phenotype each immune cell by the range of its functional proteins for the first time. Housed in its software enabled IsoLight and IsoSpark detection systems, IsoPlexis provides new and accessible layers of biological data at the single-cell level and the ability to interrogate the secreted proteome, the phosphoproteome, and the metabolome from single cells for the first time. This has allowed researchers to connect more deeply to in vivo biology and predict complex responses to therapies and disease in cancer immunotherapy, cell and gene therapy, COVID-19, autoimmune disease, and many other areas.

"We are grateful to our new and existing investors for their support of our vision," said Sean Mackay, Chief Executive Officer and Co-founder of IsoPlexis. "With more than 100 systems placed and a strong team of over 200 employees, we have laid an incredibly strong foundation for future growth at the convergence of single-cell biology, proteomics, and multi-omics. Welook forward to deploying this capital to accelerate our commercial efforts as we work to leverage our powerful biology to impact the future of advanced medicines."

About IsoPlexis

IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in-vivo biology and develop more precise and personalized therapies. Our integrated systems named as a top innovation or design by the Scientist Magazine, Fierce, BIG Innovation and Red Dot, among others are used globally to advance the field of single-cell biology into new 'omic possibilities as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Ourproducts have been adopted by researchers around the world, including 15 of the top 15 global pharmaceutical companies and by approximately 45% of comprehensive cancer centers. Visithttp://www.isoplexis.com to learn more.

Investor Contact:Carrie Mendivil[emailprotected]

Media Contact:Jon Chen, VP of Marketing[emailprotected]

SOURCE IsoPlexis

Single Cell Proteomics | The Superhuman Cell Company | IsoPlexis

Follow this link:
IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors - PRNewswire

GHz-Class NMR Opens New Scientific Research Window for Discoveries and Novel Insights in Functional Structural Biology and Disease Biology – Business…

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced that three world-leading institutions are now accelerating their research into functional structural biology and human disease with new Bruker ultra-high field nuclear magnetic resonance (NMR) spectrometers installed in 2020. Novel GHz-class NMR technology enables advanced research to obtain structural, functional and binding information of intrinsically disordered proteins (IDPs), and of partially structured proteins with key intrinsically disordered regions (IDRs), at atomic resolution under near-physiological conditions. For example, these new technological and methods capabilities now accelerate research into viral-host interactions and viral replication, as well as into proteins that are linked to neurodegenerative diseases.

The recent installation of a 1.2 GHz NMR spectrometer at the Max Planck Institute for Biophysical Chemistry in Goettingen, has already enabled their research teams to deliver new insights into the SARS-CoV-2 nucleocapsid (N) protein, and it is set to aid the deeper molecular understanding of Parkinsons and Alzheimers diseases.

Bruker's 1.2 GHz NMR magnets utilize a novel hybrid technology with high-temperature superconductor (HTS) inserts in low-temperature superconductor outer sections. The Ascend 1.2 GHz magnets are stable, homogenous, standard-bore (54 mm) magnets suitable for high-resolution and solid-state NMR.

Using ultra-high field NMR, scientists at the Max Planck Institute (MPI) and the German Center for Neurodegenerative Diseases (DZNE) have shown that the SARS-CoV-2 N protein and host ribonucleic acids (RNA) jointly condense into tiny droplets akin to membraneless organelles, when the virus enters a host cell. This fast liquid-liquid phase separation (LLPS) inside the cytoplasm of the host cell is a characteristic capability of IDPs and IDRs, and sheds new light on how the virus replicates, and offers new targets for drug development.

Professor Christian Griesinger, Director and Scientific Member at the Max Planck Institute for Biophysical Chemistry in Goettingen, commented: The new 1.2 GHz spectrometer will allow us to characterize droplets and oligomers of IDPs that are key markers in diseases such as COVID-19, neurodegenerative diseases and cancer, and which cannot be studied using crystallography or cryo-EM.

Dr. Markus Zweckstetter, Professor at the University of Goettingen and Group Leader at the German Center for Neurodegenerative Diseases, added: Our first experiments after the installation of the new ultra-high field NMR system have focused on the SARS-CoV-2 nucleocapsid N-protein that is of key relevance for viral-host interactions and viral replication biology. The liquid-like properties of viral replication machineries in combination with the many intrinsically disordered regions of the N-protein make this research ideally suited for GHz-class NMR.

Dr. Falko Busse, President of the Bruker BioSpin Group stated: The fourth quarter acceptance at the Max Planck Institute follows installations of two 1.2 GHz NMRs at CERM (University of Florence) and at ETH Zuerich earlier in 2020. We are proud to provide enabling technology for pushing the boundaries in functional structural biology and advanced materials science.

Dr. Busse continued: We are also pleased that in December 2020, we have received an order for a second Swiss 1.2 GHz system from a consortium of the University of Zuerich, ETH Zuerich and the Biozentrum of the University of Basel. For 2021, we anticipate the installation of 4-5 GHz-class NMRs, as we have used 2020 to ramp our capacity.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: http://www.bruker.com

View post:
GHz-Class NMR Opens New Scientific Research Window for Discoveries and Novel Insights in Functional Structural Biology and Disease Biology - Business...

Global Cell Biology Cloud Computing Market Revenue Analysis Report with Future Business Scope and New Investment Plans for the Next Five Years -…

The Cell Biology Cloud Computing Market study added by ResearchMoz, exhibits a comprehensive analysis of the growth trends present in the global business scenario. The study further presents conclusive data referring to the commercialization aspects, industry size and profit estimation of the market.

Cell Biology Cloud Computing Market analysis on global market is a thorough study that offers a select combination of skillful market realities. The study shows changing market trends as well as the size of individual segments in this market. This report mentions various top players involved in this market. Analysis of the Global Cell Biology Cloud Computing Market begins with a market-based outline and underlines the current information on the global market, complemented by data on the current situation.

Get Sample Copy of this Report @

https://www.researchmoz.us/enquiry.php?type=S&repid=2655551

Key Vendors are Involved in Industry:

Accenture, Amazon Web Services, Benchling, Cisco Systems, Dell Emc, IBM, DXC Technology, Oracle, ScaleMatrix, IPERION, NovelBio

Cell Biology Cloud Computing Breakdown Data by TypePublic Cloud ComputingPrivate Cloud ComputingHybrid Cloud ComputingCell Biology Cloud Computing Breakdown Data by ApplicationGenomicsDiagnosticsClinical TrialsPharma ManufacturingOthers

Market predictions for possible growth opportunities have been mentioned clearly. This report is a detailed description of the Cell Biology Cloud Computing Market sector which presents a blend of research expertise and business strategies. It also projects market trends along with the increasing scope for the individual sectors.

Insightful case studies from some significant industry experts have also been encapsulated. Various factors responsible for market growth have been examined at length. Cell Biology Cloud Computing Market report also offers analytical data on the bargaining power of vendors and buyers.

Get Flat 20% Discount On Latest Publish [emailprotected]:

https://www.researchmoz.us/enquiry.php?type=D&repid=2655551

The global Cell Biology Cloud Computing market report also indicates a narrowed decisive summary of the global market. Along with this, multiple factors which have affected the advancement and improvement in a positive as well as negative manner are also studied in the report. On the contrary, the various factors which will be acting as the opportunities for the development and growth of the market in the forecasted period are also mentioned.

The Cell Biology Cloud Computing Market report focuses on the requirements of the clients from several global Market regions such as North America, Latin America, Asia-Pacific, Europe, and India.

Benefits of Cell Biology Cloud Computing Market:

Table of Content:

Cell Biology Cloud Computing Market Research Report 2020-2026

Chapter 1: Industry Overview

Chapter 2: Cell Biology Cloud Computing Market International and Market Analysis

Chapter 3: Environment Analysis of Cell Biology Cloud Computing

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Market Revenue Status

Chapter 6: Analysis of Revenue by Regions and Applications

Chapter 7: Analysis of Cell Biology Cloud Computing Market Key Manufacturers

Chapter 8: Sales Price and Gross Margin Analysis

Enquiry Before Buying:

https://www.researchmoz.us/enquiry.php?type=E&repid=2655551

*Dont miss out on business opportunities in Cell Biology Cloud Computing Market. Speak to our analyst and gain crucial industry insights that will help your business grow and If you have any special requirements, please let us know and we will offer you the report as you want.

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Media Release: https://www.researchmoz.us/pressrelease

Follow Me On: http://amarketresearchreports.blogspot.com/

https://neighborwebsj.com/

Originally posted here:
Global Cell Biology Cloud Computing Market Revenue Analysis Report with Future Business Scope and New Investment Plans for the Next Five Years -...

BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson’s Disease – BioSpace

CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ -- BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of BayerAG,in collaboration withMemorialSloan Kettering Cancer Center(MSK), announcedtodaythat the U.S. Food and Drug Administration (FDA) has clearedtheirInvestigational New Drug (IND) application toproceedwith aPhase 1(Ph1)study in patients with advanced Parkinson's disease (PD).This is the first trial in the United States to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson's disease.Under the IND, BlueRockand MSK willexecute aPh1 clinical trial to evaluate the safety, tolerability andpreliminaryefficacyof DA01 in patients with PD.

"This is a big step for the stem cell field to finally test a truly "off-the-shelf" dopamine neuron product in human PD patients," said Lorenz Studer, MD, scientific co-founder of BlueRock and Director, Center for Stem Cell Biology at MSK. "We are also grateful for the visionary support by NYSTEM, the NY state-sponsored stem cell program that supported the earlier stages of this project."

"This trial is the culmination of a decade of arduous collaborative work that is based on very rigorous science. It is an important milestone on the road towards regenerative brain repair," said Viviane Tabar, MD, founding investigator of BlueRock and Chair of MSK's Department of Neurosurgery. "It is a real privilege and very exciting to be able to participate in both the bench science and the actual surgical intervention, here at MSK. Our collaborators at Weill Cornell Neurology will also be an integral part of the trial."

"Today, thereisno disease-modifying treatment for Parkinson's. Through this trial and those to follow, we hope to change that,"stated EmileNuwaysir, Ph.D., President and Chief Executive Officer of BlueRock. "Our therapy is intended to replace the midbrain dopaminergic neurons lost in the degenerative condition to rebuild the neural circuit, and thereby restore motor controlto Parkinson's patients. This could shift the treatment paradigm for millions ofPD patients, as well as demonstrate for the first time that degenerative disease is, in principle, reversible. We believe this would represent an enormous step forthe PD community worldwide, and formedicine."

The trial plans to enroll ten patients starting with a first clinical site at Weill Cornell Medicinein the initial open-label study. The primary objective of thePh1study is to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant. The secondary objectives of the study are to assess the evidence of transplanted cell survival and motor effects at one- and two-years post-transplant, to evaluate continued safety and tolerability at two years, and to assess feasibility of transplantation.

About Parkinson's DiseaseParkinson's disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. The worsening of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. At diagnosis, it is estimated that patients have already lost 60-80% of their dopaminergic neurons.Parkinson's disease often starts with a tremor in one hand. Other symptoms are rigidity, cramping and dyskinesias. Parkinson's disease is the second most common neurodegenerative disorder, impacting more than 7.5 million people, including 1.3 million people in North America.

About BlueRock TherapeuticsBlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics' cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology and immunology indications. BlueRock Therapeutics' cell differentiation technology recapitulates the cell's developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock Therapeutics was founded in 2016 by Versant Ventures and Bayer AG and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG (through its Leaps by Bayer unit) and Versant Ventures. The company was fully acquired by Bayer in 2019. BlueRock Therapeutics' culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit bluerocktx.com.

About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, visit bayer.com.

DisclosuresDr. Studer has intellectual property rights and interests and financial interests related to BlueRock. Dr. Tabar has financial interests related to BlueRock. Researchers at Memorial Sloan Kettering Cancer Center, including Dr. Studer, developed stem cell-derived dopaminergic neurons for the treatment of neurodegenerative diseases, and MSK licensed this intellectual property to BlueRock. MSK has institutional financial interests related to this intellectual property and BlueRock.

Forward-Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on BlueRock's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing of our clinical trial for DA01; our results regarding the safety, tolerance and efficacy of DA01 cell transplantation for patients with Parkinson's disease; and ongoing FDA and other regulatory requirements regarding the development of DA01. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Except as expressly required by law, BlueRock does not undertake an obligation to update or revise any forward-looking statement. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

View original content to download multimedia:http://www.prnewswire.com/news-releases/bluerock-therapeutics-in-collaboration-with-memorial-sloan-kettering-cancer-center-receives-ind-clearance-for-da01-in-parkinsons-disease-301202742.html

SOURCE BlueRock Therapeutics

Read the original here:
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease - BioSpace

Study monitors spatial shifts of liver gene expression in relationship to the circadian clock – News-Medical.net

Nothing in biology is static. Biological processes fluctuate over time, and if we are to put together an accurate picture of cells, tissues, organs etc., we have to take into account their temporal patterns. In fact, this effort has given rise to an entire field of study known as "chronobiology".

The liver is a prime example. Everything we eat or drink is eventually processed there to separate nutrients from waste and regulate the body's metabolic balance. In fact, the liver as a whole is extensively time-regulated, and this pattern is orchestrated by the so-called circadian clock, our body's internal metronome, as well as biochemical signals and eating rhythms.

But the liver is actually divided into small repeating units called "lobules", in which distinct zones perform different functions. This intricate spatial organization is known as "liver zonation". For example, the breakdown of sugars during digestion takes place preferentially on one side of the lobule, the so-called central zone, while the production of glucose while we rest from stores such as fat, occurs on the other side of the liver, at the portal side.

So far, liver zonation has only been studied statically, looking into what each zone does independently of time, and vice-versa. And given how central the liver is in mammalian physiology, the two research approaches have to join efforts to understand how temporal and spatial liver programs interact.

In a first ever study, scientists at EPFL and the Weizmann Institute of Science, led by Professors Felix Naef at EPFL's School of Life Sciences and Shalev Itzkovitz at the Weizmann, have been able to monitor the spatial shifts of gene expression within liver lobules in relationship to the circadian clock. Studying this link is a focus of Naef's research, which has previously uncovered connections between the circadian clock and the liver's proteins, our cell cycles, and even the 3D structure of chromatin, the tightly packaged DNA in the cell nucleus.

The study came out of a EPFL-Weizmann joint grant from the Rothschild Caesarea Foundation.

By exploiting the ability to analyze liver tissue in every individual cell, the researchers studied approximately 5000 genes in liver cells at several timepoints throughout the 24-hour day. They then statistically classified the space-time patterns they uncovered with a model that can capture both spatial and temporal variations in the levels of messenger RNA (mRNA), a marker of gene expression.

The study revealed that many of the liver's genes seem to be both zonated and rhythmic, meaning that they are regulated by both their location in the liver and the time of the day. These dually regulated genes are mostly linked to key functions of the liver, e.g. the metabolism of lipids, carbohydrates, and amino acids, but also include a few genes that have never been associated with metabolism, e.g. genes related to chaperone proteins, which help other biomolecules change their 3D structure or even assemble and disassemble.

The work reveals a richness of space-time gene expression dynamics of the liver, and shows how compartmentalization of liver function in both space and time is hallmark of metabolic activity in the mammalian liver."

Felix Naef, EPFL's School of Life Sciences

Source:

Journal reference:

Droin, C., et al. (2021) Space-time logic of liver gene expression at sub-lobular scale. Nature Metabolism. doi.org/10.1038/s42255-020-00323-1.

Here is the original post:
Study monitors spatial shifts of liver gene expression in relationship to the circadian clock - News-Medical.net